Ironwood Pharmaceuticals Inc. Class A Common Stock (IRWD)

About IRWD

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric pati…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

100

Website

ironwoodpharma.com

Fundamentals

1-day range

$3.96$4.35

Market cap

$727.59M

P/E (trailing)

5.46

P/E (forward)

2.93

EPS (trailing)

$0.79

Dividend yield

—

Beta

0.21

Avg. volume

2.40M

Forecasts

4 analyst ratings

Ironwood Pharmaceuticals Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• IRWD

  Ironwood Pharmaceuticals Inc. Class A Common Stock

  $4.13

  ▼ 2.59%
  Market cap $727.59MP/E 5.46
  $1.01$5.78
• DRUG

  Bright Minds Biosciences Inc. Common Stock

  $72.74

  ▼ 2.41%
  Market cap $723.93MP/E —
  $53.99$170
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $747.88MP/E —
  $32.04$124.82
• CTMX

  CytomX Therapeutics Inc. Common Stock

  $3.22

  ▼ 5.99%
  Market cap $690.12MP/E —
  $1.9$8.21
• OCS

  Oculis Holding AG Ordinary shares

  $12.21

  ▼ 1.77%
  Market cap $689.43MP/E —
  $10.52$34.48
• PHAR

  Pharming Group N.V. ADS each representing 10 ordinary shares

  $11.7

  ▼ 0.68%
  Market cap $766.28MP/E 88.15
  $0.8338$1.82
• ACRS

  Aclaris Therapeutics Inc. Common Stock

  $6.01

  ▼ 2.44%
  Market cap $772.34MP/E —
  $1.74$6.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/6/2026
• Ironwood Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/6/2026
• Ironwood Pharmaceuticals (NASDAQ:IRWD) Raises Full-Year Guidance on Strong LINZESS Sales Despite Q2 Miss
  ChartMill · 8/6/2026
• Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M Est
  Benzinga · 8/6/2026
• Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate
  Benzinga · 8/6/2026
• Rare Stock Picks In July 2026 - From 22 Discerning Analysts
  SeekingAlpha · 8/5/2026
• Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth
  SeekingAlpha · 7/31/2026

• Silber Jeffrey · July 20, 2026 · Grant

  137.0K
• Silver Ronald · July 7, 2026 · Sale

  127.9K @ $4.52
• Jay Shepard · June 16, 2026 · Grant

  63.5K
• Kessler Marla L · June 16, 2026 · Grant

  63.5K
• Currie Mark G · June 16, 2026 · Grant

  63.5K
• Duane Jon R · June 16, 2026 · Grant

  63.5K
• Julie McHugh · June 16, 2026 · Sale

  21.6K @ $3.73
• Julie McHugh · June 16, 2026 · Grant

  63.5K
• Catherine Moukheibir · June 16, 2026 · Grant

  63.5K
• Alexander J. Denner · June 16, 2026 · Grant

  63.5K
• Alexander J. Denner · June 15, 2026 · Grant

  4.1K
• Silver Ronald · May 19, 2026 · Grant

  25.0K
• Alexander J. Denner · March 17, 2026 · Sale

  5.8K @ $3.31
• Alexander J. Denner · March 17, 2026 · Sale

  6.72M @ $3.05
• Alexander J. Denner · March 13, 2026 · Grant

  4.5K

Institutional Ownership

March 31, 2026

Total shares held

163.15M

Total value held

$545.10M

Institutional holders

218